SG11201408054RA - Pegylated oxm variants - Google Patents
Pegylated oxm variantsInfo
- Publication number
- SG11201408054RA SG11201408054RA SG11201408054RA SG11201408054RA SG11201408054RA SG 11201408054R A SG11201408054R A SG 11201408054RA SG 11201408054R A SG11201408054R A SG 11201408054RA SG 11201408054R A SG11201408054R A SG 11201408054RA SG 11201408054R A SG11201408054R A SG 11201408054RA
- Authority
- SG
- Singapore
- Prior art keywords
- peg30
- international
- lys
- oxm
- fms
- Prior art date
Links
- 102400000319 Oxyntomodulin Human genes 0.000 abstract 7
- 101800001388 Oxyntomodulin Proteins 0.000 abstract 7
- -1 9-fluorenylmethoxycarbonyl (Fmoc) Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 229930190657 Rupin Natural products 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Inorganic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261655367P | 2012-06-04 | 2012-06-04 | |
| PCT/IL2013/050481 WO2013183052A1 (en) | 2012-06-04 | 2013-06-04 | Pegylated oxm variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408054RA true SG11201408054RA (en) | 2015-01-29 |
Family
ID=49711501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201702228QA SG10201702228QA (en) | 2012-06-04 | 2013-06-04 | Pegylated oxm variants |
| SG11201408054RA SG11201408054RA (en) | 2012-06-04 | 2013-06-04 | Pegylated oxm variants |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201702228QA SG10201702228QA (en) | 2012-06-04 | 2013-06-04 | Pegylated oxm variants |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10537646B2 (enExample) |
| EP (1) | EP2854838B1 (enExample) |
| JP (2) | JP6290193B2 (enExample) |
| KR (1) | KR102092025B1 (enExample) |
| CN (2) | CN109096387B (enExample) |
| AU (2) | AU2013273135B2 (enExample) |
| CA (1) | CA2875599C (enExample) |
| CL (1) | CL2014003307A1 (enExample) |
| CO (1) | CO7160097A2 (enExample) |
| EA (1) | EA201492269A1 (enExample) |
| HK (1) | HK1209045A1 (enExample) |
| IL (1) | IL236034B (enExample) |
| IN (1) | IN2015DN00003A (enExample) |
| MX (1) | MX362432B (enExample) |
| PE (1) | PE20150181A1 (enExample) |
| SG (2) | SG10201702228QA (enExample) |
| WO (1) | WO2013183052A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
| PE20142405A1 (es) | 2012-04-19 | 2015-01-25 | Opko Biolog Ltd | Variantes de oxintomodulina de accion prolongada y metodos de produccion de las mismas |
| EP2854838B1 (en) | 2012-06-04 | 2018-10-17 | OPKO Biologics Ltd. | Pegylated oxm variants |
| EP2922867B1 (en) | 2012-11-20 | 2021-07-21 | OPKO Biologics Ltd. | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| CN106519015B (zh) * | 2014-09-23 | 2020-04-17 | 深圳市图微安创科技开发有限公司 | 胃泌酸调节素类似物 |
| PH12017501089B1 (en) | 2014-12-10 | 2022-06-22 | Opko Biologics Ltd | Methods of producing long acting ctp-modified growth hormone polypeptides |
| KR20180014754A (ko) * | 2015-05-29 | 2018-02-09 | 옵코 바이오로직스 리미티드 | 페길화된 옥신토모둘린 변이체 |
| AU2016280867B2 (en) | 2015-06-19 | 2020-02-27 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| WO2017075583A2 (en) * | 2015-10-30 | 2017-05-04 | The Research Foundation For The State University Of New York | Oxyntomodulin analogs and methods of making and using same |
| CN113546159B (zh) * | 2015-12-29 | 2023-09-08 | 派格生物医药(苏州)股份有限公司 | 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途 |
| WO2017212494A1 (en) * | 2016-06-09 | 2017-12-14 | Opko Biologics Ltd. | Long-acting oxyntomodulin formulation and methods of producing and administering same |
| KR102618424B1 (ko) | 2016-07-11 | 2023-12-26 | 옵코 바이오로직스 리미티드 | 지속성 응고 인자 vii 및 그 제조 방법 |
| CN108299554B (zh) * | 2017-01-13 | 2021-05-25 | 博瑞生物医药（苏州）股份有限公司 | 胃泌酸调节素类似物 |
| CN111094331B (zh) * | 2017-08-16 | 2024-03-29 | 东亚St株式会社 | 酰化胃泌酸调节素肽类似物 |
| US12441776B2 (en) | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
| KR20210126088A (ko) | 2019-02-11 | 2021-10-19 | 옵코 바이오로직스 리미티드 | 지속성 glp-2 유사체 |
| WO2025184364A1 (en) * | 2024-03-01 | 2025-09-04 | University Of Notre Dame Du Lac | Self-assembling depots of adjuvant peptide therapies |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| DE3421468A1 (de) | 1984-06-08 | 1985-12-19 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| ATE110571T1 (de) | 1988-05-06 | 1994-09-15 | Toray Industries | Stabile interferon-beta-zusammensetzung. |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| JP3148298B2 (ja) | 1991-09-02 | 2001-03-19 | 帝人株式会社 | 軽量複合成形物の製造法 |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
| US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
| WO1996014336A1 (en) | 1994-11-07 | 1996-05-17 | Kyowa Hakko Kogyo Co., Ltd. | Novel oxyntomodulin |
| DE69624488T2 (de) | 1995-08-10 | 2003-06-26 | Kazunori Kataoka | Blockcopolymere mit funktionellen gruppen an beiden kettenenden |
| IL119029A0 (en) | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
| IL139285A0 (en) | 1998-04-28 | 2001-11-25 | Applied Research Systems | Peg-lhrh analog conjugates, their preparation and use |
| US6617276B1 (en) | 2000-07-21 | 2003-09-09 | Johnson Matthey Public Limited Company | Hydrocarbon trap/catalyst for reducing cold-start emissions from internal combustion engines |
| IL139400A0 (en) | 2000-11-01 | 2001-11-25 | Yeda Res & Dev | Long-acting cytokine derivatives and pharmaceutical compositions comprising them |
| JP2004515533A (ja) | 2000-12-14 | 2004-05-27 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 代謝障害を治療するためのペプチドｙｙおよびペプチドｙｙアゴニスト |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| KR100870013B1 (ko) | 2002-08-27 | 2008-11-21 | 삼성전자주식회사 | 박막 트랜지스터 어레이 기판 및 그 제조 방법 |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| PL1620118T3 (pl) | 2003-04-08 | 2014-11-28 | Yeda Res & Dev | Leki odwracalnie pegylowane |
| KR101135244B1 (ko) * | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
| GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| SI1891105T1 (sl) * | 2005-06-13 | 2012-07-31 | Imp Innovations Ltd | Analogi oksintomodulina in njihovi učinki na prehranjevalno vedenje |
| US7928058B2 (en) | 2006-02-22 | 2011-04-19 | Merck Sharp & Dohme Corp. | Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition |
| TWM345876U (en) | 2008-06-17 | 2008-12-01 | Yong-Xuan Ji | Auxiliary device for mobile engine |
| MX2011003117A (es) | 2008-09-19 | 2011-04-21 | Nektar Therapeutics | Conjugados polimericos de peptidos terapeuticos. |
| NZ595848A (en) | 2009-03-20 | 2014-04-30 | Hanmi Science Co Ltd | Method for preparing a site-specific physiologically active polypeptide conjugate |
| AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
| JO2976B1 (en) | 2009-12-22 | 2016-03-15 | ايلي ليلي اند كومباني | Axentomodulin polypeptide |
| EP2668286A4 (en) | 2011-01-24 | 2015-07-01 | Univ Ben Gurion | METHOD FOR EVALUATING A MENTAL DISEASE |
| US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
| EA201391764A1 (ru) | 2011-06-02 | 2014-07-30 | Пролор Байотек Инк. | Агонисты рецептора glp-1/глюкагона длительного действия |
| HRP20190265T1 (hr) | 2011-06-17 | 2019-04-05 | Hanmi Science Co., Ltd. | Konjugat koji sadrži oksintomodulin i fragment imunoglobulina i njegova uporaba |
| PE20142405A1 (es) | 2012-04-19 | 2015-01-25 | Opko Biolog Ltd | Variantes de oxintomodulina de accion prolongada y metodos de produccion de las mismas |
| EP2854838B1 (en) | 2012-06-04 | 2018-10-17 | OPKO Biologics Ltd. | Pegylated oxm variants |
-
2013
- 2013-06-04 EP EP13800444.5A patent/EP2854838B1/en active Active
- 2013-06-04 CA CA2875599A patent/CA2875599C/en active Active
- 2013-06-04 CN CN201811001898.9A patent/CN109096387B/zh active Active
- 2013-06-04 MX MX2014014890A patent/MX362432B/es active IP Right Grant
- 2013-06-04 HK HK15109770.0A patent/HK1209045A1/xx unknown
- 2013-06-04 EA EA201492269A patent/EA201492269A1/ru unknown
- 2013-06-04 US US14/405,597 patent/US10537646B2/en active Active
- 2013-06-04 SG SG10201702228QA patent/SG10201702228QA/en unknown
- 2013-06-04 JP JP2015515646A patent/JP6290193B2/ja active Active
- 2013-06-04 AU AU2013273135A patent/AU2013273135B2/en active Active
- 2013-06-04 IN IN3DEN2015 patent/IN2015DN00003A/en unknown
- 2013-06-04 WO PCT/IL2013/050481 patent/WO2013183052A1/en not_active Ceased
- 2013-06-04 SG SG11201408054RA patent/SG11201408054RA/en unknown
- 2013-06-04 KR KR1020147037080A patent/KR102092025B1/ko active Active
- 2013-06-04 PE PE2014002372A patent/PE20150181A1/es not_active Application Discontinuation
- 2013-06-04 CN CN201380040700.7A patent/CN104684576B/zh active Active
-
2014
- 2014-12-02 IL IL236034A patent/IL236034B/en active IP Right Grant
- 2014-12-03 CL CL2014003307A patent/CL2014003307A1/es unknown
- 2014-12-26 CO CO14284184A patent/CO7160097A2/es unknown
-
2015
- 2015-01-08 US US14/592,641 patent/US9821070B2/en active Active
-
2017
- 2017-11-02 US US15/801,554 patent/US20180050113A1/en not_active Abandoned
-
2018
- 2018-02-07 JP JP2018020172A patent/JP6549741B2/ja active Active
- 2018-03-06 AU AU2018201623A patent/AU2018201623B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408054RA (en) | Pegylated oxm variants | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201811150WA (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201908740VA (en) | Sustained release delivery systems comprising traceless linkers | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201408646VA (en) | Dimeric protein with triple mutations | |
| SG11201811148SA (en) | Cell penetrating peptide (cpp)-mediated ev loading | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201810970WA (en) | Anti-egfr antibody drug conjugates | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201810853UA (en) | Anti-tnfrsf25 antibodies |